Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.38 |
| ▸ | CES1 | P23141 | 4/20 | 0.38 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464492 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL2606207 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL9857817 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL13302332 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL16940067 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL15271047 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL11405438 | 1.00 | THRB (0.44) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL14306652 | 0.97 | HTR1A (0.42) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL7156662 | 0.94 | HTR1A (0.40) | THRBTSHRHTR1ADRD2HTR2A | |
| SCHEMBL10396090 | 0.88 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20240025848-A1 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-25 | — | — | US | disclosed |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-9650456-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-2825574-B1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150031845-A1 | Process For Producing Polydienes | BRIDGESTONE CORPORATION (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2825574-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013138270-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTSONE CORPORATION (JP) | 2013-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025848-A1 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | LIPA, LIPC, TLR9 | THRB 3413/4885TSHR 3143/4885HTR1A 3967/4885 |
| US-20230302138-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | THRB 2609/4885TSHR 2262/4885HTR1A 3916/4885 |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | LIPA, LIPC, TLR9 | THRB 3413/4885TSHR 3143/4885HTR1A 3967/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | THRB 2609/4885TSHR 2262/4885HTR1A 3916/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | THRB 4690/4885TSHR 3323/4885HTR1A 4697/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | THRB 1435/4885TSHR 2016/4885HTR1A 4509/4885 |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | THRB 2609/4885TSHR 2262/4885HTR1A 3916/4885 |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | DGKB, DGKG, DGKA | THRB 3876/4885TSHR 4629/4885HTR1A 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.